Expands international footprint with entry into Asia-Pacific, building on recent CE Mark and UK approvalsATLANTA, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced it has received approval from the New Zealand Medicines and Medical Devices Safety Authority (MEDSAFE) for its FemBloc Permanent Birth Control. This approval confirms that FemBloc ...

WARSAW, Ind., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Lake City Bank announced its plans to invest $12 million in the company’s Innovation and Technology Center as part of its Downtown Warsaw Headquarters Campus expansion. The project represents the bank’s continued investment in Warsaw and Kosciusko County, where it has invested $23 million in Downtown Warsaw and $31 million total countywide to date since 2010. Construction on the 35,600 square foot office building will begin in early September, with completion ...

临床研究进展 - 公司已在急性髓系白血病(AML) Phase 1临床试验第一队列的第二名患者中完成第二剂CER-1236给药[1] - 经机构审查委员会(IRB)批准实施多剂量强化方案 基于前两名患者的药代动力学数据显示细胞扩增 新方案使每位受试者的细胞输注量较原方案增加一倍[1] - 首席医疗官表示方案调整旨在评估多剂量输注的可行性与安全性 并为增加剂量的影响提供数据[2] 学术交流与协议展示 - 研究调查员在血液肿瘤学会第13届年会展示研究方案海报 标题为"靶向TIM-4-l的自体嵌合吞噬受体T细胞CER-1236治疗急性髓系白血病首次人体研究"[2] - 海报展示活动于2025年9月3日在休斯顿乔治布朗会议中心举行[2] 试验设计与测量指标 - Phase 1/1b研究为多中心开放标签试验 针对复发/难治性AML 或存在可测量残留病变的缓解期患者 或TP53突变的MDS/AML新确诊患者[3] - 研究包含剂量递增和扩展两个阶段 主要终点包括不良事件(SAE/AE)发生率 剂量限制性毒性及总体缓解率(ORR) 完全缓解(CR)和可测量残留病变(MRD)[3] - 次要终点包含药代动力学(PK)参数[3] 技术平台与治疗机制 - 公司开发嵌合吞噬受体T细胞(CER-T)技术平台 整合先天性与适应性免疫特性 通过吞噬机制消除肿瘤细胞[4] - CER-T技术相比现有CAR-T疗法可能具有差异化优势 有望扩展至血液恶性肿瘤和实体瘤治疗领域[4] - 先导候选产品CER-1236已进入血液恶性肿瘤临床试验阶段[4]

A secure, U.S.-developed software and controls platform purpose-built for Eos Z3 battery systems to power and protect America’s energy future DawnOSTM will be offered to customers as part of a turnkey solution EDISON, N.J., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Eos Energy Enterprises, Inc. (NASDAQ: EOSE) ("Eos" or the “Company”), an American energy company and the leading innovator in designing, sourcing, manufacturing, and providing zinc-based battery energy storage systems (BESS) manufactured in the United S ...

赎回条款 - 公司宣布赎回全部7700万美元未偿还本金总额的2029年到期850%可转换优先票据 赎回价格为票面金额100%加上应计未付利息 赎回日期为2025年9月23日 [1] - 票据持有人可在2025年9月19日下午5点前转换 转换率为每1000美元本金兑换1279743股A类普通股 其中因赎回通知额外增加109536股 [2] - 公司选择通过交付A类普通股加现金零头方式结算转换 利息自赎回日起停止计提 [1][2] 业务概况 - 公司为全球领先比特币挖矿技术企业 提供包括设备采购、物流运输、数据中心设计建设及运营管理的全链条挖矿解决方案 [3] - 业务布局覆盖新加坡、美国、挪威和不丹 同时为人工智能高需求客户提供先进云服务能力 [3]

Boise, Idaho, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Idaho Copper Corp. (OTC: COPR), a critical minerals developer advancing a flagship copper-molybdenum project in Idaho, today announced the engagement of international investor relations specialists MZ Group (MZ) to lead a strategic investor relations and financial communications program across all key markets. MZ Group will work closely with Idaho Copper management to develop and implement a comprehensive capital markets strategy designed to increase the comp ...

Agreement to Serve as a Model for Future Collaborations to Create a National Network of TSDF Partnerships DURHAM, N.C., Sept. 08, 2025 (GLOBE NEWSWIRE) -- 374Water Inc. (NASDAQ: SCWO) (“374Water”), a global leader in organic waste destruction technology and services for the municipal, federal, and industrial markets, today announced a Waste Destruction Services (“WDS”) collaboration agreement focused on PFAS eradication with Crystal Clean, a leading provider of environmental and waste management solutions t ...

New Agreements Result in Removal of Two Affiliated Utilities & Parent Company from Company’s 2024 Iowa Patent Litigation CORSICANA, Texas, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Birchtech Corp. (TSX: BCHT) (OTCQB: BCHT) ("Birchtech" or the "Company"), a leader in specialty activated carbon technologies for sustainable air and water treatment, today announced non-exclusive agreements with two coal-fired power utilities, affiliated with one another, named as defendants in the Company’s July 2024 lawsuit filed in ...

DURHAM, N.C., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company (“Pelthos” or the “Company”) committed to commercializing innovative therapeutic products for high unmet patient needs, today announced that Scott Plesha, CEO, and Frank Knuettel II, CFO, will participate in the upcoming September conferences: H.C. Wainwright 27th Annual Global Investment Conference and the Investor Summit Group Q3 Virtual Conference. Investor Conference Details: H.C ...

New York, NY, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Globalink Investment Inc. (OTC Pink: GLLI, GLLIW, GLLIR, GLLIU) (“Globalink” or the “Company”), a special purpose acquisition company, announced today that on September 4, 2025, it caused to be deposited $0.15 per public share, totaling $10,890.15 (the “Extension Payment”) into its trust account (the “Trust Account”) with Continental Stock Transfer and Trust Company (“Continental”) to extend the deadline to complete its initial business combination from Septe ...